

WHAT'S IL-23 GOT TO DO WITH IT?

Targeted Therapies in the Management of IBD



Monday, October 28, 2024

7:00 PM ET Dinner

7:30–9:00 PM ET Presentation

Philadelphia Marriott
Salon Ballroom H-J

This event is neither sponsored by nor endorsed by ACG.



WHAT'S IL-23 GOT TO DO WITH IT?

Targeted Therapies in the Management of IBD



Activity Description

Cytokines, such as interleukin (IL)-23, are key drivers of intestinal inflammation in patients with inflammatory bowel disease. While all IL-23–targeted agents neutralize IL-23, differences in antibody structure can improve the ability of these agents to capture this inflammatory cytokine from a main source of production, namely CD64-positive myelocytes. As the treatment landscape of IL-23–targeted therapies continues to expand, it is crucial that gastroenterology clinicians understand the differentiating aspects of current and emerging treatments in order to develop an efficacious, lasting, and individualized treatment plan for each patient.

In this CME Outfitters live symposium, expert faculty will review the functions of Fc gamma receptors, CD64 and its connection with IL-23, the molecular attributes of anti-IL-23 therapies, in vivo data on expression of CD64 monocytes, and the most recent clinical trial data differentiating the anti-IL-23 agents. To demonstrate these concepts, animated 3-D models will be included in the educational program and available to attendees.

Target Audience

Gastroenterologists, gastroenterology fellows, physician associates (PAs), nurse practitioners (NPs), and nurses

Financial Support

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.- both are Johnson & Johnson companies.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

- Assess the role of pro-inflammatory cytokines in driving inflammation in the pathogenesis of IBD
- Classify the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis
- Evaluate the clinical implications of anti-IL-23 agents used in the treatment of IBD to bind to CD64 receptors on IL-23–producing cells

Faculty

Marla Dubinsky, MD (Moderator)

Professor of Pediatrics and Medicine
Co-Director, Susan and Leonard Feinstein IBD Clinical Center
Director, Marie and Barry Lipman IBD Preconception and Pregnancy Clinic
Icahn School of Medicine Mount Sinai New York
Chief, Division of Pediatric GI and Nutrition
Mount Sinai Kravis Children's Hospital
New York, NY

David P. Hudesman, MD, FACP, AGAF

Director, Inflammatory Bowel Disease Center at NYU Langone Health
Professor of Medicine, NYU Grossman School of Medicine
New York, NY

Corey A. Siegel, MD, MS

Director, Center for Digestive Health
Section Chief, Gastroenterology and Hepatology
Dartmouth Hitchcock Medical Center
Constantine and Joyce Hampers Professor of Medicine
Geisel School of Medicine at Dartmouth
Hanover, NH

WHAT'S IL-23 GOT TO DO WITH IT?

Targeted Therapies in the Management of IBD



Accreditation



Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



IPCE

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME)

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC)

This activity is designated for 1.5 contact hours. **Note to Nurse Practitioners:** The content of this CNE activity pertains to Pharmacology. **California Residents:** This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC's provider number is CEP15510.



PAs (AAPA)

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.



RCP Canada

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.



MIPS

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Certificate of Participation

This activity was certified for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*[™].

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education Credit for learning and change.



ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

WHAT'S IL-23 GOT TO DO WITH IT?

Targeted Therapies in the Management of IBD



Marla Dubinsky, MD
(Moderator)

Professor of Pediatrics and Medicine

Co-Director, Susan and Leonard
Feinstein IBD Clinical Center

Director, Marie and Barry Lipman IBD
Preconception and Pregnancy Clinic

Icahn School of Medicine
Mount Sinai New York

Chief, Division of Pediatric
GI and Nutrition

Mount Sinai Kravis Children's Hospital
New York, NY

Marla C. Dubinsky, MD, is a Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai, New York, New York. Dr. Dubinsky received her medical degree from Queen's University, Canada. She completed her pediatric residency at Alberta Children's Hospital, Calgary, Canada, and her clinical fellowship in gastroenterology and nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She completed her research fellowship in inflammatory bowel disease (IBD) at Cedars-Sinai Medical Center in Los Angeles, California, where she served as the Director of the Pediatric IBD Center before going to Mount Sinai as the Chief of Pediatric Gastroenterology and Nutrition at the Mount Sinai Kravis Children's Hospital and as Co-Director of the Susan and Leonard Feinstein IBD Clinical Center. Dr. Dubinsky is also Co-Director of the IBD Preconception and Pregnancy Planning Clinic at Mount Sinai. She is Co-Founder of Mi-Test Health as well as Cornerstones Health, a non-profit organization dedicated to enhancing and transforming communication between health care providers, patients, and industry partners through a creative, comprehensive, and expert-based educational program. She is also Co-Founder of Trellus Health, a resilience-driven, connected health solution for chronic conditions, leading with IBD. She is also a recipient of the 2022 Sherman Prize.

Dr. Dubinsky has been engaged in IBD clinical and translational research for over two decades. Her primary research focuses on developing predictive models and web-based decision support tools that integrate clinical markers and biomarkers to predict the natural history of IBD and response to therapy. She has a keen interest in personalized medicine in IBD, and her research uncovers predictors of rapid disease progression with the goal of preventing complications by altering treatment plans. Dr. Dubinsky is the principal investigator of multiple large longitudinal cohorts including the Road to Prevention Multiplex Family Program at Mount Sinai with over 700 enrolled participants, with a goal of using multi-omics data to predict the development of IBD in unaffected family members. She is co-investigator of the Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn's Disease (RISK) study and senior author on the manuscript presenting a model to predict the natural history of pediatric Crohn's disease. Dr. Dubinsky is very committed to women's reproductive health in IBD, and in addition to her research in this field she is Co-Founder of WECARE in IBD, an organization dedicated to the health of women with IBD. She is very committed to leading the next generation of female leaders in the field of gastroenterology. She has lectured widely, both nationally and internationally, and has published in more than 340 peer-reviewed journals, including *New England Journal of Medicine*, *Gastroenterology*, *Lancet*, *JAMA*, *The Journal of Pediatric Gastroenterology and Nutrition*, *The Journal of Crohn's and Colitis*, *Inflammatory Bowel Diseases*, and *The American Journal of Gastroenterology*.

DISCLOSURES

Dr. Dubinsky reports the following financial relationships:

Advisory Board and

Consultant: AbbVie Inc.; Abivax; AstraZeneca; Bristol Myers Squibb Company; Celltrion Inc.; Janssen Biotech, Inc.; Lilly; Merck & Co., Inc.; Pfizer Inc.; Prometheus Biosciences; Spyre Therapeutics, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Other financial or material

support: (PI) Janssen Biotech, Inc. Road to Prevention; (Co-PI) Helmsley Foundation PK Dashboard Optimized Dosing of Infliximab Is Not Inferior to Standard Reactive Dosing: The OPTIMIZE Trial

WHAT'S IL-23 GOT TO DO WITH IT?

Targeted Therapies in the Management of IBD



**David P. Hudesman,
MD, FACG, AGAF**

Director, Inflammatory Bowel Disease
Center at NYU Langone Health

Professor of Medicine, NYU Grossman
School of Medicine

New York, NY

David P. Hudesman, MD, is Director of the Inflammatory Bowel Disease Center at NYU Langone Health and Professor of Medicine at the NYU School of Medicine. He specializes in the diagnosis and treatment of inflammatory bowel disease (IBD) and in the provision of integrated, seamless, patient-centered care. His research is focused on the development of biomarkers and evaluation and optimization of new medical therapies for the treatment of Crohn's disease and ulcerative colitis. Dr. Hudesman serves on the Educational Affairs Committee of the American College of Gastroenterology, the Professional Membership Committee of the Crohn's Colitis Foundation, and the Quality Committee of the American Gastroenterological Association.

DISCLOSURES

Dr. Hudesman reports the following financial relationships:

Consultant: AbbVie Inc.; Avalo Therapeutics, Inc.; Bristol Myer Squibb Company; Eli Lilly and Company; Fresenius Kabi; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus; and Takeda Pharmaceuticals U.S.A., Inc.

Research Support: Janssen Pharmaceuticals, Inc. and Pfizer Inc.

WHAT'S IL-23 GOT TO DO WITH IT?

Targeted Therapies in the Management of IBD



Corey A. Siegel, MD, MS

Director, Center for Digestive Health

Section Chief, Gastroenterology
and Hepatology

Dartmouth Hitchcock Medical Center

Constantine and Joyce Hampers
Professor of Medicine

Geisel School of Medicine at Dartmouth

Hanover, NH

Corey A. Siegel, MD, MS, is the Director of the Center for Digestive Health, Section Chief of Gastroenterology and Hepatology, and the Co-Director of the Inflammatory Bowel Disease (IBD) Center at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth. Dr. Siegel attended college at Tufts University and then received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as Chief Medical Resident. He then completed a fellowship in gastroenterology at Dartmouth Hitchcock followed by a fellowship in IBD at Massachusetts General Hospital in Boston.

Dr. Siegel's research interests include understanding risk-benefit tradeoffs in IBD, developing models to predict outcomes in Crohn's disease, creating tools to facilitate shared decision-making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ), the Crohn's and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel has lectured nationally and internationally and published numerous journal articles and book chapters on this and other topics in IBD. He is the founder of the BRIDGe group, an international research collaboration of IBD investigators, and is currently the co-chair of the Crohn's and Colitis Foundation Quality of Care Program (IBD Qorus). Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.

DISCLOSURES

Dr. Siegel reports the following financial relationships:

Advisory Board: AbbVie Inc.; Bristol Myers Squibb Company; Buhmann; Janssen Pharmaceuticals, Inc.; Lilly; Napo Therapeutics; Pfizer Inc.; Prometheus Biosciences, Inc.; Roivant Sciences; Takeda Pharmaceuticals U.S.A., Inc.; and Trellus Health Inc.

Consultant: AbbVie Inc.; Boomerang; Bristol Myers Squibb Company; Buhmann; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Biosciences, Inc.; Prometheus Labs; and Takeda Pharmaceuticals U.S.A., Inc.

Grants: AbbVie Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer Inc.

Other financial or material support: Dr. Corey Siegel is co-founder of MiTest Health, LLC (software company). Technology developed by MiTest Health, LLC has been licensed to Takeda.

WHAT'S IL-23 GOT TO DO WITH IT?

Targeted Therapies in the Management of IBD



Disclosure Declarations

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Peer Reviewers

Jeffrey Helfand, DO—no disclosures to report.

Albert Eubanks, Jr., RN—no disclosures to report.

CME Staff/Planners

Susan Perry—no disclosures to report.

Kasey Brandt, PharmD—no disclosures to report.

Sandra Caballero, PharmD—no disclosures to report.

Scott J. Hershman, MD, FACEHP, CHCP—no disclosures to report.

Sharon Tordoff—no disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

WHAT'S IL-23 GOT TO DO WITH IT?

Targeted Therapies in the Management of IBD



Instructions for Interactive Technology

Use one of the iPads provided at your table to answer polling questions, view onsite presentations, and submit questions to the faculty. Please see additional information below.

ASK FACULTY A QUESTION

Select the Ask Question tab below the slide viewer to submit a question. If your question is for a specific faculty member, please include their name. Your question will be shared with the faculty for the question-and-answer portion of the session.

VIEW AND TAKE NOTES ON PRESENTATION SLIDES

Select the Take Notes tab to take notes during the meeting. All of the notes you take during the meeting will be emailed to the address provided within 5 business days.

Obtaining Credit

To receive CME/CE credit for this activity, scan the QR code to create an account.



Downloadable Resources

Downloadable resources will be available at cmeoutfitters.com/IL23MMresources.

Engage with Us

Follow us [@cmeoutfitters](https://twitter.com/cmeoutfitters) for announcements about upcoming CME opportunities, healthcare news, and more!

Thank you for joining us today!

